University of Patras
Λειτουργική μελέτη του ρόλου νέων γονιδίων στην αύξηση των επιπέδων της εμβρυϊκής αιμοσφαιρίνης του ανθρώπου
Abstract
dc:descriptionHemoglobinopathies, sickle cell anemia and β-thalassemia, are the most common Mendelian disorders today, considered as the most critical health problems worldwide. The molecular characterization of both sickle cell anemia and β-thalassemia has shown their clinical and hematologic heterogeneity. Patients with exactly the same β-globin genotypes exhibit dramatically variable clinical manifestations. It is observed that increased levels of fetal hemoglobin may ameliorate disease symptoms. The identification of genetic modifiers and the understanding of their function that affects fetal hemoglobin levels in adult individuals are essential to predict the severity of the disease as well as the development of new therapeutic approaches through the induction of HbF.Hydroxyurea is the only pharmaceutical agent approved by FDA (Food and Drug Administration) that is widely used for HbF induction in sickle cell anemia and β-thalassemia patients. Notwithstanding, drug response varies, while the potential side effects of its long-term use, requires the understanding of the intricate mechanisms of its function that have not yet been fully clarified. It has already been shown that several protein factors act as modifiers of fetal hemoglobin production, exerting their effect through different molecular pathways.In the present study, we investigated the role of SIN3A as modifier of fetal hemoglobin production, as its interaction with KLF10 has already been documented, the latter being known as a modifier of γ-globin gene expression. We show that genomic variants identified in this gene are associated with a) β-thalassemia disease severity (rs11072544, rs7166737) and b) response to hydroxyurea treatment (rs7166737) in β-hemoglobinopathies patients. The findings of this study further highlight that fetal hemoglobin production is the result of a complex interaction between, in cis and in trans of the globin gene cluster, genetic modifiers that lead to the observed clinical phenotype.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gravia, Aikaterini
- Γραβιά, Αικατερίνη
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/38932